Myriad Genetics Strengthens Financial Position with New Facility
Myriad Genetics, Inc. (NASDAQ: MYGN), known as a pioneer in molecular diagnostic testing and precision medicine, has successfully closed a significant five-year senior secured term loan credit facility. This funding, totaling up to $200 million, comes from OrbiMed, a renowned investment firm in the healthcare sector. The facility comprises $125 million in funded capital, with an option for an additional $75 million to be borrowed until June 30, 2027. This new financial backing matures on July 31, 2030, with its interest rate tied to the one-month secured overnight financing rate (SOFR) plus 6.50%, ensuring a minimum SOFR floor of 2.50%.
Insights from Leadership
Scott Leffler, the Chief Financial Officer of Myriad Genetics, expressed enthusiasm about this partnership, stating, "We are excited to partner with OrbiMed, a leading global healthcare investment firm. We value their insight and financial backing, which supports our ability to pursue our near-term objectives and long-term growth plan." This capital access positions Myriad to further its strategic initiatives, with plans to discuss this in detail during their upcoming second-quarter earnings call.
Matthew Rizzo, a General Partner at OrbiMed, echoed this sentiment, noting, "We are pleased to partner with Myriad to support the company's growth strategy. We believe Myriad's portfolio of diagnostic tests provides critical insights that enable healthcare providers to deliver better care to patients."
Implications of the New Credit Facility
The newly acquired credit facility replaces the previous asset-based lending (ABL) arrangement of Myriad Genetics. This facility is secured by a comprehensive lien on virtually all assets owned by Myriad and its subsidiaries, reinforcing the company’s financial security and operational capacity.
In the context of Myriad's ambitions, this move is a pivotal moment, as the company aims to leverage these resources to advance its research and enhance product offerings. Details regarding the credit facility have been outlined in the company's Current Report on Form 8-K submitted to the Securities and Exchange Commission.
About Myriad Genetics
Myriad Genetics is at the forefront of molecular diagnostics, dedicated to improving health outcomes through innovative testing. The company's molecular tests are designed to assess the risk of various diseases, providing critical data that informs treatment strategies across different medical fields. By focusing on areas where molecular insights can significantly enhance patient care and reduce healthcare costs, Myriad remains committed to advancing personal health and well-being.
About OrbiMed
OrbiMed is a distinguished healthcare investment firm with over $17 billion in assets under its watch. The firm invests across the globe, supporting ventures from startup levels to well-established multinational corporations. They deliver tailored financing solutions critical for building world-class healthcare companies, employing a global team of over 130 professionals stationed in key financial hubs.
Investor and Media Contact Information
The recent strategic developments have sparked interest in Myriad Genetics, with stakeholders eager to see how this facility will be utilized. For further inquiries, investors can reach out to Matt Scalo at (801) 584-3532 or via email.
For media inquiries, Katie Schraml can be contacted at (224) 875-4493.
Frequently Asked Questions
What is the amount of the new credit facility announced by Myriad Genetics?
The new credit facility amounts to $200 million, with an initial funding of $125 million and an option to borrow an additional $75 million.
How does this facility impact Myriad Genetics' growth strategy?
This facility enables Myriad Genetics to access substantial capital aimed at enhancing their growth strategies and expanding their offerings in molecular diagnostics.
Who managed the transaction for Myriad Genetics?
Evercore served as the exclusive financial advisor for Myriad Genetics concerning this credit facility transaction.
What is the maturity date of the newly secured loan?
The credit facility is set to mature on July 31, 2030.
How will this credit facility affect patient care?
The additional funding will assist Myriad Genetics in furthering innovations that can lead to improved diagnostics, thereby enhancing patient care and treatment outcomes.
